Therapeutic targeting of noncoding RNAs (ncRNAs), such as microRNAs (miRNAs) and
long noncoding RNAs (lncRNAs), represents an attractive approach for the treatment of …

RNA-based therapies, including RNA molecules as drugs and RNA-targeted small
molecules, offer unique opportunities to expand the range of therapeutic targets. Various …

Compared with traditional drug therapy, nanomedicines exhibit intriguing biological features
to increase therapeutic efficiency, reduce toxicity and achieve targeting delivery. This review …

Abstract Recently, United States Food and Drug Administration (FDA) and European
Commission (EC) approved Alnylam Pharmaceuticals' RNA interference (RNAi) therapeutic …

Due to a series of systemic and intracellular obstacles in nucleic acid (NA) therapy, including
fast degradation in blood, renal clearance, poor cellular uptake, and inefficient endosomal …

Although many patients with newly diagnosed Ewing sarcoma can become long-term
survivors, relapse remains an important clinical problem for which there is no standard …

Lack of selectivity together with severe side effects in conventional cancer treatment have
afforded the development of new strategies based on gene therapy. Nowadays, gene …

Soft tissue and bone sarcomas are malignancies of mesenchymal origin, and more than 50
subtypes are defined. For most sarcomas, locally advanced or unresectable disease is still …

Pediatric malignancies including Ewing sarcoma (EwS) feature a paucity of somatic
alterations except for pathognomonic driver-mutations that cannot explain overt variations in …

Introduction: The unique structure of bone and cartilage makes the systemic delivery of free
drugs to those connective tissues very challenging. Consequently, effective and targeted …